What is AbbVie Inventory-to-Revenue?
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AbbVie's Average Total Inventories for the quarter that ended in Mar. 2024 was $4,172 Mil. AbbVie's Revenue for the threemonths ended in Mar. 2024 was $12,310 Mil. AbbVie's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.34.
AbbVie's Inventory-to-Revenue for the quarter that ended in Mar. 2024 increased from Dec. 2023 (0.28) to Dec. 2023 (0.34)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. AbbVie's Days Inventory for the three months ended in Mar. 2024 was 92.99.
Inventory Turnover measures how fast the company turns over its inventory within a year. AbbVie's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.98.
AbbVie Inventory-to-Revenue Historical Data
The historical data trend for AbbVie's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
AbbVie Inventory-to-Revenue Chart
AbbVie Annual Data | ||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.05 | 0.06 | 0.06 | 0.06 | 0.07 |
AbbVie Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.30 | 0.28 | 0.29 | 0.28 | 0.34 |
Competitive Comparison of AbbVie's Inventory-to-Revenue
For the Drug Manufacturers - General subindustry, AbbVie's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where AbbVie's Inventory-to-Revenue falls into.
AbbVie Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
AbbVie's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (A: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) |
= | ( (3579 | + | 4099) | / | 2 ) | / | 54318 |
= | 3839 | / | 54318 | ||||
= | 0.07 |
AbbVie's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue (Q: Mar. 2024 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Dec. 2023 ) | + | Total Inventories (Q: Mar. 2024 )) | / | count ) | / | Revenue (Q: Mar. 2024 ) |
= | ( (4099 | + | 4245) | / | 2 ) | / | 12310 |
= | 4172 | / | 12310 | ||||
= | 0.34 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie(NYSE:ABBV) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
AbbVie's Days Inventory for the threemonths ended in Mar. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2024 ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | 4172 | / | 4094 | * | 365 / 4 | |
= | 92.99 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
AbbVie's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Mar. 2024 ) | / | Average Total Inventories (Q: Mar. 2024 ) |
= | 4094 | / | 4172 | |
= | 0.98 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of AbbVie's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
AbbVie (AbbVie) Business Description
Industry
GURUFOCUS.COM »STOCK LIST »Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Inventory-to-Revenue
Comparable Companies
MRK PFE JNJ AMGN BMY GILD BIIB OGN SCLX AMRN LLY XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4568 TSE:4519 XTER:BAYN SHSE:600276
Traded in Other Exchanges
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
Website
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Executives
Nicholas Donoghoe | officer: SVP, Enterprise Innovation | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Susan E Quaggin | director | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Jennifer L. Davis | director | 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202 |
Richard A Gonzalez | officer: Chairman of the Board and CEO | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Elaine K. Sorg | officer: Sr. V.P., U.S. Commercial Ops. | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Perry C Siatis | officer: EVP, GC and Secretary | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Jeffrey Ryan Stewart | officer: SVP, US Commercial Operations | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Kevin K Buckbee | officer: SVP, Controller | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Scott T Reents | officer: SVP, Chief Financial Officer | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Azita Saleki-gerhardt | officer: SVP, Operations | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Carrie C Strom | officer: SVP & Pres Global Allerg Aesth | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Roxanne S Austin | director | 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245 |
Timothy J. Richmond | officer: EVP, Chief HR Officer | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Michael Severino | officer: EVP, R&D and CSO | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Henry O Gosebruch | officer: Chief Strategy Officer | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092 |
AbbVie (AbbVie) Headlines
From GuruFocus
Abbvie Inc at Wolfe Research Healthcare Conference Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at JPMorgan Healthcare Conference (Virtual) Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc To Acquire Cerevel Therapeutics Transcript
By GuruFocus Research • 01-22-2024
Q1 2022 Abbvie Inc Earnings Call Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Cowen Health Care Conference Transcript
By GuruFocus Research • 01-22-2024
Q4 2021 Abbvie Inc Earnings Call Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Wolfe Research Healthcare Conference (Virtual) Transcript
By GuruFocus Research • 01-22-2024
Q4 2022 Abbvie Inc Earnings Call Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Evercore ISI HealthCONx Virtual Conference Transcript
By GuruFocus Research • 01-22-2024
Q2 2022 Abbvie Inc Earnings Call Transcript
By GuruFocus Research • 01-22-2024